Total Funding
73
58
Total FundingSeries D raised
Growth Score
5 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
16633
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
- Sam Jackson: Chief Medical Officer
- Andrew Yost: Chief Business Officer
About the Company
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
The company was founded in 2018 and is based in San Francisco, California, United States.
